Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : BARDA
Deal Size : $220.0 million
Deal Type : Funding
Details : Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : BARDA
Deal Size : $220.0 million
Deal Type : Funding
Lead Product(s) : Berzosertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : UCLA Jonsson Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Potential COVID-19 Treatment Identified in UCLA-Led Lab Study
Details : Berzosertib, which is licensed by Merck KGaA, Darmstadt, Germany, is being investigated in separate early- and mid-stage clinical trials in combination with chemotherapy as a possible treatment for small-cell lung cancer, ovarian cancer and other types o...
Product Name : M6620
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2021
Lead Product(s) : Berzosertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : UCLA Jonsson Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adrecizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with Adrecizumab showed an encouraging outcome in this limited data set, seven out of eight patients survived the observation period. Adrecizumab targets Adrenomedullin to restore endothelial barrier function and impaired vascular integrity.
Product Name : HAM8101
Product Type : Antibody
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Adrecizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the contract, Vibalogics will produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany, expected to yield thousands of vaccine doses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Univercells
Deal Size : Undisclosed
Deal Type : Partnership
Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine
Details : Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with Univercells Technologies’ NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 14, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Univercells
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Anixa Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics
Details : The strategic collaboration focuses on discovery and development of anti-viral drug candidates for COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Anixa Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ifx-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands.
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Ifx-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : US Government
Deal Size : Undisclosed
Deal Type : Partnership
Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus
Details : Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 19, 2020
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : US Government
Deal Size : Undisclosed
Deal Type : Partnership